加速表型测试BC试剂盒对血流感染患者的真实世界影响:改善结局与抗菌药物管理研究中的一项准实验多中心研究
这项多中心准实验研究比较了实施Accelerate PhenoTest BC Kit(AXDX)前后血流感染患者的抗菌药物管理指标与临床结局。共纳入854例患者(AXDX前435例、AXDX后419例),AXDX后组至最佳治疗时间中位数缩短17.2小时(23.7小时 vs 40.9小时,P<.0001),首次抗菌药物调整和降阶梯时间也缩短,但死亡率、住院时间和不良药物事件无显著差异。
要点
- AXDX后组至最佳治疗时间中位数为23.7小时,较AXDX前组的40.9小时缩短17.2小时(P<.0001)。
- AXDX后组首次抗菌药物调整中位时间13.9小时 vs AXDX前组24.2小时(P<.0001)。
- AXDX后组首次抗菌药物降阶梯中位时间27.2小时 vs AXDX前组36.0小时(P=.0004)。
核心结论
- 对于血流感染,使用AXDX与至最佳治疗时间、首次抗菌药物调整时间和抗菌药物降阶梯时间的显著缩短相关。
研究设计与样本
- 多中心准实验研究,比较实施AXDX前后血流感染住院患者(排除污染菌)的实验室和临床数据,AXDX后组接受AXDX检测,AXDX前组接受替代的病原体鉴定和药敏试验。
- 共纳入854例血流感染患者,AXDX前组435例,AXDX后组419例。
主要发现
- 至最佳治疗时间中位数AXDX后组为23.7小时,AXDX前组为40.9小时,AXDX后组缩短17.2小时(P<.0001)。
- 首次抗菌药物调整中位时间AXDX后组为13.9小时,AXDX前组为24.2小时(P<.0001)。
- 首次抗菌药物降阶梯中位时间AXDX后组为27.2小时,AXDX前组为36.0小时(P=.0004)。
- 死亡率AXDX前组8.7% vs AXDX后组6.0%,住院时间AXDX前组7.0天 vs AXDX后组6.5天,不良药物事件两组间无显著差异。
- 在革兰阴性菌血症患者中,AXDX后组住院时间5.4天 vs AXDX前组6.4天(P=.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bloodstream infections (BSIs) are a leading cause of morbidity and mortality. The Improving Outcomes and Antimicrobial Stewardship study seeks to evaluate the impact of the Accelerate PhenoTest BC Kit (AXDX) on antimicrobial use and clinical outcomes in BSIs. METHODS: This multicenter, quasiexperimental study compared clinical and antimicrobial stewardship metrics, prior to and after implementation of AXDX, to evaluate the impact this technology has on patients with BSIs. Laboratory and clinical data from hospitalized patients with BSIs (excluding contaminants) were compared between 2 arms, 1 that underwent testing on AXDX (post-AXDX) and 1 that underwent alternative organism identification and susceptibility testing (pre-AXDX). The primary outcomes were time to optimal therapy (TTOT) and 30-day mortality. RESULTS: A total of 854 patients with BSIs (435 pre-AXDX, 419 post-AXDX) were included. Median TTOT was 17.2 hours shorter in the post-AXDX arm (23.7 hours) compared with the pre-AXDX arm (40.9 hours; P<.0001). Compared with pre-AXDX, median time to first antimicrobial modification (24.2 vs 13.9 hours; P<.0001) and first antimicrobial deescalation (36.0 vs 27.2 hours; P=.0004) were shorter in the post-AXDX arm. Mortality (8.7% pre-AXDX vs 6.0% post-AXDX), length of stay (7.0 pre-AXDX vs 6.5 days post-AXDX), and adverse drug events were not significantly different between arms. Length of stay was shorter in the post-AXDX arm (5.4 vs 6.4 days; P=.03) among patients with gram-negative bacteremia. CONCLUSIONS: For BSIs, use of AXDX was associated with significant decreases in TTOT, first antimicrobial modification, and time to antimicrobial deescalation.
引用
- Bhalodi AA, MacVane SH, Ford B, et al. Real-World Impact of the Accelerate PhenoTest BC Kit on Patients With Bloodstream Infections in the Improving Outcomes and Antimicrobial Stewardship Study: A Quasiexperimental Multicenter Study. Clin Infect Dis. 2022. PMID: 34718456. doi:10.1093/cid/ciab921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。